Debu Tripathy, MD,

Debu Tripathy, MD, discusses real-world strategies for CDK4/6 inhibitor use and the importance of HER2 testing in HER2-positive metastatic breast cancer.

Debu Tripathy, MD, discusses the current state of the HER2-positive breast cancer treatment paradigm.

Debu Tripathy, MD, discusses the implications of results from the phase 3 NALA trial in patients with HER2-positive metastatic breast cancer with brain metastases.

Dr. Tripathy reviews the safety and efficacy data from a phase 2 non-randomized study of tucatinib-trastuzumab-capecitabine regimen in patients with leptomeningeal metastasis.

Debu Tripathy, MD, discusses the emergence of genomics research in breast cancer.

Debu Tripathy, MD, discusses efforts being made to minimize the risk of disease recurrence in patients with early-stage HER2-positive breast cancer.

Debu Tripathy, MD, discusses updated results of the phase 3 MONALEESA-7 trial in hormone receptor–positive, HER2-negative breast cancer.

Debu Tripathy, MD, discusses treatment de-escalation in HER2-positive breast cancer.

Debu Tripathy, MD, discusses fam-trastuzumab deruxtecan-nxki versus ado-trastuzumab emtansine in HER2-expressing breast cancers.

Debu Tripathy, MD, discusses genomically guided therapy in breast cancer.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses known elements of COVID-19.

Debu Tripathy, MD, discusses personalized therapy options in metastatic breast cancer.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the MONALEESA-7 trial in hormone receptor-positive breast cancer.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combination strategies being investigated with CDK4/6 inhibitors in breast cancer.

For more than 100 years, endocrine therapy has been used for the treatment of breast cancer; since that time, we have learned much about the role of estrogen in the biology of normal breast cancer development.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the impact of T-DM1 in HER2-positive breast cancer.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of pertuzumab in HER2-positive breast cancer.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combination strategies with CDK4/6 inhibitors for the treatment of patients with hormone receptor (HR)-positive breast cancer.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses frontline endocrine therapies for patients with hormone receptor (HR)-positive breast cancer.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the progression of biosimilars in oncology.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of biosimilars in oncology.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the management of hormone-receptor (HR)-positive early-stage breast cancer.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the FDA approval of olaparib (Lynparza) for patients with BRCA-positive breast cancers and the impact it has had on clinical practice. Tripathy shared this insight in an interview during the 35th Annual Miami Breast Cancer Conference.

Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses lurbinectedin (PM01183) for patients with breast cancer.

Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neratinib (Nerlynx) for the treatment of patients with HER2-positive breast cancer.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy in HER2-positive breast cancer.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses standard and emerging advances in the treatment of patients with HER2-positive breast cancer.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neoadjuvant treatment strategies in HER2-positive breast cancer.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the potential role of immunotherapy in the treatment of patients with HER2-positive breast cancer.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses agents that are available and in development in the neoadjuvant setting as treatments for patients with HER2-positive breast cancer.